Who Owns Keros Therapeutics Stock?
NASDAQ: KROSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 99.50%
- Institutions (% of float)
- 104.31%
- Held by insiders
- 4.62%
- Institutional holders
- 194
- Institutions 95.4%
- Insiders 4.6%
- Public and other 0.0%
Who owns Keros Therapeutics stock?
Institutional investors own about 99.5% of Keros Therapeutics's shares, spread across 194 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 4.62% of KROS.
The largest institutional holders are Blackrock Inc. (14.24%), Nantahala Capital Management, LLC (7.19%) and AQR Capital Management, LLC (4.93%). Together, the top 10 institutions control 51.5% of shares outstanding. In their latest filings, 6 of the top 10 institutions increased their KROS positions and 2 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of KROS
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Blackrock Inc. | 2.79M | 14.24% | +15.9% |
| Nantahala Capital Management, LLC | 1.41M | 7.19% | +3.7% |
| AQR Capital Management, LLC | 967.86K | 4.93% | +138.1% |
| Vanguard Capital Management LLC | 833.60K | 4.25% | +0.3% |
| Orbimed Advisors LLC. | 759.15K | 3.87% | 0.0% |
| Mackenzie Financial Corporation | 742.84K | 3.79% | +18.2% |
| Federated Hermes, Inc. | 707.05K | 3.60% | +0.9% |
| Vanguard Portfolio Management LLC | 652.63K | 3.33% | -4.3% |
| Madison Avenue Partners, LP | 626.58K | 3.19% | 0.0% |
| Qube Research & Technologies Ltd | 608.84K | 3.10% | -16.0% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of KROS
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 595.32K | 3.03% |
| iShares Trust-iShares Russell 2000 ETF | 477.30K | 2.43% |
| BlackRock Funds-BlackRock Advantage Small Cap Core Fund | 454.75K | 2.32% |
| Federated Hermes MDT Series-Federated Hermes MDT Small Cap Core Fund | 382.34K | 1.95% |
| VANGUARD HORIZON FUNDS-Vanguard Strategic Small-Cap Equity Fund | 258.66K | 1.32% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 220.85K | 1.13% |
| TIAA-CREF Funds-Nuveen Quant Small Cap Equity Fund | 190.04K | 0.97% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 178.52K | 0.91% |
| iShares Trust-iShares Russell 2000 Value ETF | 175.34K | 0.89% |
| Vanguard Explorer Fund | 171.15K | 0.87% |
Frequently asked questions
Who is the largest shareholder of Keros Therapeutics?
Blackrock Inc. is the largest institutional shareholder of KROS, owning 14.24% of shares outstanding (2.79M shares) as of its latest 13F filing.
What percentage of Keros Therapeutics is owned by institutions?
Institutions own about 99.5% of KROS shares and 104.3% of the public float.
How much of Keros Therapeutics do insiders own?
Insiders, such as officers and directors, own about 4.62% of KROS shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.